Alisertib Shows Promise in Soft-Tissue Sarcoma

Alisertib yielded promising progression-free survival in advanced/metastatic soft-tissue sarcoma patients, though it did not meet its primary response rate endpoint.

Source: CancerNetwork - August 16, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: News Sarcoma Source Type: news